The North Central London (NCL) Medicines Optimisation Board (NCL MOB) aims to provide strategic pharmacy leadership and collaboration for medicines optimisation projects and opportunities across NCL through shared decision making between primary, secondary, tertiary, community and social care.
The Board supports the implementation of recommendations from Regional Medicines Optimisation Committees (RMOCs) and NCL JFC. NCL MOB also proactively identifies ways to improve patient care and experience, and champions the safe use of medicines across NCL.
NCL MOB provides oversight to the Integrating Pharmacy and Medicines Optimisation (IPMO) Programme, which supports delivery of collaborative medicines optimisation priorities across NCL ICS.
NCL MOB delegates responsibilities to several subgroups, including the NCL Shared Care Group (who lead the development and update of NCL shared care guidelines and factsheets, and maintain the NCL Red List).
The following sub-groups feed into MOB:
Provider Trust Chief Pharmacist Collaborative
Medicines and Medical Devices Safety Group
Shared Care Group
ICB Heads of Medicines Management Collaborative
NCL Inhaler Sustainability Group
Antimicrobial Stewardship Group